Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Can a rituxumab biosimilar be used for a high grade lymphoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Alabama Birmingham

Rituximab (Rituximab) was the landmark addition to treatment of B cell-Non Hodgkin Lymphoma in the late 1990s. It changed the treatment for B cell NHL. Rituximab is also used in many other off label indications (as for example ITP, TTP etc.). Recently two bio-similars were approved by US FDA: Truxim...

How do you incorporate prognostic mutations into your management of primary myelofibrosis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

Mutational testing is critical to help diagnose, prognosticate, and make treatment decisions in primary myelofibrosis. I obtain JAK2/CALR/MPL on all patients and also obtain an extended NGS panel to determine if there are any high molecular risk markers, such as SRSF2, EZH2, IDH1/2, and ASXL1. Mutat...

How do you approach a patient with metastatic inflammatory TNBC at diagnosis with a good PS?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Icahn School of Medicine at Mount Sinai

I would approach this patient with weekly nab-paclitaxel and atezolizumab if she was PDL-1 positive (just like the Impassion Trial, NEJM 2018:379;2018-21). If the tumor (actually the stroma) was PD-L1 negative, then I would treat with paclitaxel and carboplatin (80 mg/m2 and AUC 2 days 1, 8, and 15 ...

When would you consider active surveillance for a patient with metastatic RCC?

1

What is your recommendations for vaccines to prevent shingles in CLL patients?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic College of Medicine and Science (Scottsdale)

In October 2017, the U.S. FDA licensed the adjuvanted, recombinant zoster vaccine (Shingrix). Phase 1/2a studies in immunocompromised subjects, including autologous hematopoietic cell transplant recipients and HIV- infected adults, have confirmed that Shingrix is immunogenic and safe with no documen...

Do you alter your management of Stage I-II DLBCL if it's double or triple hit?

1

When do you recommend patients get vaccinations with respect to their chemotherapy course?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

It depends on the nature of the treatment program and on the patient’s immune system. For treatments that are not B-cell lymphodepleting, routine vaccinations can be administered routinely, presuming no underlying immunodeficiency. For patients receiving anti-CD20 monoclonal antibodies, we typically...

Why do we immediately perform CNS staging with a LP at diagnosis of ALL when the risk of seeding is highest with a high lymphoblast count?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Ohio State University James Cancer Center

We wait until circulating blasts are cleared from PB before doing LP.

How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · NIH

If the colitis completely resolves, I would consider a colonoscopy to be sure that subclinical microscopic lymphocytic colitis has completely resolved. If not, I would consider 3 dose of infliximab to reduce recurrence of colitis. Then once off steroids, I would restart single agent anti-PD1.

What would be your preferred adjuvant regimen for ampullary carcinoma (pancreatic histology) in patient with pre-existing neuropathy?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Jefferson Kimmel Cancer Center

The approach to adjuvant therapy for ampullary cancer is always controversial. Few studies have addressed this directly. The EORTC trial reported in 1999 evaluated 5-FU and radiotherapy vs observation in pancreatic and ampullary cancer and showed no benefit in the ampullary subset (Ann Surg 1999).in...